Show simple item record

dc.contributor.authorColquhoun, David
dc.contributor.authorKeech, Anthony
dc.contributor.authorHunt, David
dc.contributor.authorMarschner, Ian
dc.contributor.authorSimes, John
dc.contributor.authorGlasziou, Paul
dc.contributor.authorWhite, Harvey
dc.contributor.authorBarter, Philip
dc.contributor.authorTonkin, Andrew
dc.contributor.authorHamilton-Craig, Ian
dc.contributor.authoret al.
dc.date.accessioned2018-07-31T04:52:09Z
dc.date.available2018-07-31T04:52:09Z
dc.date.issued2004
dc.identifier.issn0195668Xen_US
dc.identifier.doi10.1016/j.ehj.2004.03.013en_US
dc.identifier.urihttp://hdl.handle.net/10072/32165
dc.description.abstractAims: Fibrates or nicotinic acid are usually recommended for secondary prevention of coronary heart disease in patients with low plasma levels of both low-density lipoprotein cholesterol (LDL-C) ⩽140 mg/dL (⩽3.6 mmol/L) and high-density lipoprotein cholesterol (HDL-C) ⩽40 mg/dL (⩽1.03 mmol/L). The LIPID trial, a randomised, placebo-controlled trial in 9014 patients at 87 centres in Australia and New Zealand, provided an opportunity to investigate the effects of an HMG-CoA reductase inhibitor in patients with low LDL-C and low HDL-C. Methods and results: Participants in this post hoc substudy were 2073 patients aged 31–75 years with baseline LDL-C ⩽140 mg/dL (⩽3.6 mmol/L), HDL-C ⩽40 mg/dL (⩽1.03 mmol/L), and triglyceride ⩽300 mg/dL (⩽3.4 mmol/L). The relative risk reduction with pravastatin treatment was 27% for major coronary events (95% CI 8–42%), 27% for coronary heart disease mortality (95% CI 0–47%), 21% for all-cause mortality (95% CI 0–38%), and 51% for stroke (95% CI 24–69%). The number needed to treat to prevent a major coronary event over 6 years was 22. Conclusions: Treatment with pravastatin in patients with both low LDL-C and low HDL-C significantly reduced major coronary events, stroke, and all-cause mortality. The level of HDL-C is crucial to the risk of recurrent CHD events and, consequently, the benefit of lowering LDL-C.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherOxford University Pressen_US
dc.publisher.placeUnited Kingdomen_US
dc.relation.ispartofpagefrom771en_US
dc.relation.ispartofpageto777en_US
dc.relation.ispartofissue9en_US
dc.relation.ispartofjournalEuropean Heart Journalen_US
dc.relation.ispartofvolume25en_US
dc.subject.fieldofresearchcode329999en_US
dc.titleEffects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID studyen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2014-10-10T01:56:38Z
gro.hasfulltextNo Full Text
gro.griffith.authorHamilton-Craig, Ian


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record